Neuren completes enrolment in Pitt Hopkins Phase 2 trial
Filed with ASX · · 2 pages · English
Melbourne, Australia:Neuren Pharmaceuticals (ASX: NEU) today announced that enrolment of subjects into its Phase 2 clinical trial of NNZ-2591 in Pitt Hopkins syndrome has been completed. Top-line results from the trial are expected to be available in Q2 2024. Neuren CEO Jon Pilcher commented “We are grateful to all the people who have contributed to achieving this important milestone as we strive
Neuren Pharmaceuticals Limited on 6ix
Story so far
Earlier from Neuren Pharmaceuticals
- DAYBUE net sales US$66.9 million in Q3 2023
- Q3 2023 quarterly activity and cash flow report
- S&P DJI Announces September 2023 Quarterly Rebalance
- Q2 2023 quarterly activity and cash flow report
- Neuren receives US$100m for expanded DAYBUE agreement
Later from Neuren Pharmaceuticals
- P2 trial shows significant improvements in Phelan-McDermid
- Investor presentation, 18 December 2023
- Completion of enrolment in Neuren's Angelman P2 trial
- Q4 2023 quarterly activity report
- Q4 2023 Appendix 4C Cash Flow Report
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals